Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study.

Intratumoral sotigalimab combined with pembrolizumab induces a 50% objective response rate in metastatic melanoma, activating immune cells in both injected and non-injected tumors.

• Why it matters: Overcoming resistance to immune checkpoint blockers remains a challenge in metastatic melanoma treatment, necessitating new strategies to enhance immune activation and response.
• What they did: The study involved 32 ICB-naïve patients receiving intratumoral sotigalimab with pembrolizumab, assessing safety, objective response rate, and immune activation through multiomic analyses and TCR sequencing.
• The result: The combination was well tolerated, with a 50% ORR and 92% DCR, demonstrating effective immune engagement, increased T-cell clonality, and responses in non-injected tumors, supporting its potential to improve outcomes.